The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Treatment sequencing and decision-making for metastatic NETs
Nicola Fazio, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, explores treatment sequencing for metastatic pancreatic neuroendocrine tumors (panNET), highlighting factors impacting clinical decisions in NETs. With multiple therapies now available, the discussion centers on treatment prioritization based on somatostatin receptor status, tumor grade, and burden. High-grade, symptomatic tumors may benefit from early chemotherapy, while grade 1 or 2 somatostatin receptor-positive tumors are candidates for early peptide receptor radionuclide therapy (PRRT), particularly after somatostatin analog therapy. The NETTER-2 trial (NCT03972488) updates on the efficacy of PRRT in grade 2 NET reinforce these treatment guidelines. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
